RxDoctor Payments DataLook up a doctor →

Hoang le, MD

Pulmonary Disease · Fountain Valley, CANPI 1104886241

Payments from drug & device makers

$814,200in general payments, 2019–2025

Across 1,126 payments — averaging $723.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$366K
  • GSK$258K
  • Sunovion Pharmaceuticals Inc.$75K
  • Mylan Specialty L.p.$43K
  • Verona Pharma, Inc.$17K
  • Regeneron Healthcare Solutions, Inc.$12K
  • plus $43K from 11 others

What the payments were for

  • Consulting fees$57,9407%
  • Speaking & faculty fees$638,73978%
  • Travel & lodging$88,95111%
  • Food & beverage$28,4623%
  • Education$1090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$814,200 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$674,156
Medicare patients
1,116
Services billed
6,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter1,648$1,418,066
Breztri AerosphereBudesonide/Glycopyr/Formoterol1,025$684,639
OfevNintedanib Esylate51$672,559
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr427$236,565
Breo ElliptaFluticasone/Vilanterol172$85,413
Stiolto RespimatTiotropium Br/Olodaterol Hcl47$45,472
Albuterol Sulfate HfaAlbuterol Sulfate1,067$45,267
Ventolin HfaAlbuterol Sulfate512$30,208
Spiriva RespimatTiotropium Bromide21$18,282
Incruse ElliptaUmeclidinium Bromide28$15,212
Fluticasone-SalmeterolFluticasone Propion/Salmeterol75$14,579
Spiriva HandihalerTiotropium Bromide22$12,816
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate31$7,767
Fluticasone-VilanterolFluticasone/Vilanterol11$5,706
Roflumilast36$5,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$257,617$1,755,2562,275 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$11,137$736,313119 claims
AstraZenecaBreztri Aerosphere$366,339$684,6391,025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →